Dr. Layne Garrett, Au.D., tinnitus specialist and founder of Timpanogos Hearing & Tinnitus, in an audiology consultation room in American Fork, Utah

Tinnitus Treatment: What Works, What Doesn’t, and What Clinical Guidelines Actually Recommend

ByDr. Layne Garrett

By Dr. Layne Garrett, Au.D., FAAA, ABAC, CH-TM, CDP | About | YouTube | Podcast | LinkedIn

Date Published: March 29, 2026 9:00 MDT

Most people with persistent tinnitus — the ringing, buzzing, hissing, or humming in the ears that won’t go away — have been told at some point that nothing can be done. That they need to learn to live with it. Some were told this by a primary care physician who had little training in audiology. Others were told this after a single appointment with a hearing specialist whose approach began and ended with a hearing aid. A few were told this by audiologists who genuinely believed it. In almost every case, it was the wrong answer.

The evidence base for tinnitus treatment — for actually relieving the ringing, reducing how much it interferes with daily life, and in many cases making it fade significantly into the background — is more robust than the field’s reputation suggests. There are interventions with high-quality research behind them — including one with a Level A evidence recommendation from the national clinical guidelines and one FDA-approved medical device with real-world outcome data now published in peer-reviewed literature. There are also a great many products, supplements, and interventions that do not work and that the same guidelines specifically advise against.

This page covers both categories — what works, what the evidence says about how well it works, and what patients on the Wasatch Front deserve to know before committing to any course of treatment. At Timpanogos Hearing & Tinnitus, serving patients from American Fork, Spanish Fork, and South Jordan (opening Spring 2026), tinnitus care is built around the same evidence reviewed here. As a founding member of the Modern Tinnitus Specialty Center network — a national group of tinnitus-focused audiology practices built around integrated, protocol-driven care — this practice helped shape what comprehensive tinnitus treatment looks like in a clinical setting.

💡 Clinician’s Note

The patients who make the least progress with tinnitus are often those who spent years being told nothing could be done, then eventually found their way to a specialist who actually had the tools to help. By then, the neural pathways reinforcing their tinnitus response were deeply conditioned, and the emotional weight of the condition had compounded significantly. Earlier, better-informed care produces better outcomes. That’s the whole purpose of a page like this — so patients know what to ask for, and what to decline, from the very first appointment. — Dr. Layne Garrett, Au.D.

Table of Contents

Key Takeaways

  • According to the AAO-HNS Clinical Practice Guideline for Tinnitus, hearing aid evaluation is the recommended first clinical step for patients with concurrent hearing loss and tinnitus, and cognitive behavioral therapy carries the guideline’s strongest evidence rating — Level A — for persistent, bothersome tinnitus.
  • Lenire, the only FDA-approved bimodal neuromodulation device for tinnitus, produced clinically meaningful improvement in 91.5% of patients in the first real-world U.S. data published in Nature Communications Medicine(2025).
  • The AAO-HNS guideline explicitly recommends against supplements including ginkgo biloba, melatonin, and zinc for tinnitus treatment; no routine pharmaceutical has been shown to reduce tinnitus symptoms specifically.

What the Guidelines Say About Tinnitus Treatment

Tinnitus treatment — including treatment for the chronic ringing, buzzing, or hissing in the ears that affects an estimated 25 million American adults — has a clearer evidence base than most people realize, and a surprisingly long list of things that clinicians are specifically advised not to recommend. The American Academy of Otolaryngology–Head and Neck Surgery Foundation published the first evidence-based clinical practice guideline for tinnitus in 2014, and it remains the foundational clinical standard in the United States. A companion VA/DOD clinical practice guideline for tinnitus was published in 2024 in JAMA Otolaryngology–Head & Neck Surgery, providing additional guidance for adults with service-connected tinnitus.

Both guidelines share a core framework: the goal of tinnitus treatment is not necessarily to eliminate the sound, but to reduce the distress, functional impairment, and quality-of-life burden it causes. That reframing matters enormously, because patients who approach treatment expecting silence often abandon care that could genuinely help them. Patients who understand that the goal is habituation, reduced reactivity, and improved daily function are far more likely to benefit.

The AAO-HNS guideline focuses specifically on tinnitus that is both persistent (six months or longer) and bothersome — meaning it affects quality of life, sleep, concentration, mood, or relationships. This is the population most likely to seek clinical care, and the one for whom evidence-based treatment has the greatest potential to help.

The first clinical priority is a comprehensive audiologic evaluation. Tinnitus that is unilateral, persistent, or associated with hearing difficulties warrants prompt assessment. A thorough diagnostic evaluation identifies underlying conditions, establishes a baseline, and guides which interventions are most appropriate. Jumping to symptom management without adequate diagnosis is one of the most common reasons treatment fails. The complete tinnitus guide on this site covers the full diagnostic picture in depth.

Hearing Aids: The Primary Tool in Tinnitus Management

Hearing aids are the most broadly applicable, most accessible, and most frequently overlooked intervention in tinnitus care. For patients with concurrent hearing loss — which describes the majority of people with chronic tinnitus, even those who feel they hear fine in everyday conversation — properly fit hearing aids are the appropriate first clinical step and should be considered the anchor of any tinnitus treatment plan. For many patients, they are also the intervention that produces the most noticeable reduction in ear ringing during daily life, because they directly address the auditory deprivation driving the brain’s compensatory phantom sound generation.

The AAO-HNS guideline recommends hearing aid evaluation for any patient with both hearing loss and persistent, bothersome tinnitus. The reasoning is physiologically grounded: when the auditory system is deprived of normal sound input, the brain compensates by increasing its internal sensitivity — a process that amplifies the perception of phantom sounds like tinnitus. Restoring that input through amplification reduces the deprivation driving that compensation. It also restores ambient background sound, which reduces the perceptual contrast that makes tinnitus more intrusive in quiet environments. Many patients experience meaningful tinnitus relief as a direct consequence of appropriately fit amplification.

A critical distinction applies here. A hearing aid that is not properly verified does not reliably provide these benefits. Device performance depends on confirming that the amplification reaching the eardrum matches the prescriptive target for that individual’s audiogram — a process called Real Ear Measurement. Fewer than 30% of clinics nationwide perform it routinely, despite being the recommended standard from both the American Academy of Audiology and ASHA. Without verification, a hearing aid may be delivering the wrong gain at the wrong frequencies, substantially reducing its potential benefit for both speech understanding and tinnitus. For patients who tried a hearing aid in the past and found it unhelpful, the problem may not have been the device — it may have been the fitting. The article on what to do when a hearing aid didn’t fix your tinnitus explores that distinction directly, and the Real Ear Measurement pillar page covers the verification mechanics in full.

Most modern hearing aids also include built-in tinnitus sound generators that can deliver broadband noise, nature sounds, notched audio, or other signals alongside amplification. A 2021 study in the Journal of Speech, Language, and Hearing Research found that acoustic therapy delivered via hearing aids produced a statistically significant decrease in tinnitus handicap and a significant increase in heart rate variability — an objective autonomic measure — after eight weeks of use. The combination of amplification and acoustic therapy in a single device is generally more effective than sound therapy alone, and for patients with hearing loss it remains the recommended starting point before considering any additional intervention.

💡 Clinician’s Note

In my clinical experience, patients who come in saying a hearing aid “didn’t do anything” for their tinnitus often haven’t had Real Ear Measurement performed. When we verify the fitting and adjust to the prescriptive target, the difference is frequently significant — not just for speech clarity but for tinnitus habituation. I don’t consider a hearing aid properly fit without that verification, and I’d encourage patients to ask that question directly before agreeing to any fitting. — Dr. Layne Garrett, Au.D.

Sound Therapy and Tinnitus Retraining

The AAO-HNS guideline lists sound therapy as an Option — supported by evidence, appropriate for many patients, but not a uniform recommendation in the way CBT or hearing aids are. Sound therapy encompasses broadband noise, nature sounds, music, and specialized signals designed to target the tinnitus frequency. The underlying mechanism involves masking, distraction, and, with some approaches, neuroplasticity-driven habituation.

Sound therapy is most useful as a component of a larger treatment plan rather than a standalone intervention. Used in isolation with no accompanying counseling, patients may become dependent on the masking effect without achieving habituation — meaning symptoms return when the sound is removed. The article on whether sound therapy actually retrains the brain or just distracts examines this mechanism in clinical depth.

Tinnitus Retraining Therapy (TRT) combines sound therapy with directive counseling and has decades of clinical use, though the evidence base is considered moderate. The VA/DOD 2024 guideline notes that a combination of sound-based and behavioral interventions shows a robust reduction in tinnitus-related distress, with benefits outweighing risks across the collective body of evidence.

Bimodal Neuromodulation: Lenire and the Emerging Device Landscape

What Bimodal Neuromodulation Is

Bimodal neuromodulation for tinnitus involves pairing auditory stimulation with a second, non-auditory sensory input — delivered in a precisely timed sequence. The goal is to use the brain’s capacity for neuroplasticity to reduce the aberrant neural activity generating the tinnitus signal, not simply to mask it. Two different devices are currently in various stages of development and regulatory clearance using this approach, and patients researching tinnitus treatment will encounter both.

Lenire — FDA-Approved

Lenire, developed by Neuromod Devices, received De Novo approval from the FDA in March 2023 — making it the first and only FDA-approved device of its kind for tinnitus. It pairs audio tones through wireless headphones with mild electrical pulses to the tongue via a mouthpiece called the Tonguetip, stimulating the trigeminal nerve. Patients use the device at home for two 30-minute sessions per day, typically over 12 weeks, under the supervision of a qualified audiologist. Lenire is indicated for adults 18 and older with at least moderate tinnitus severity (a Tinnitus Handicap Inventory score of 38 or above) and does not require somatic tinnitus as a condition of candidacy.

Clinical trial evidence. Three large-scale trials — TENT-A1, TENT-A2, and TENT-A3 — were completed prior to FDA approval. The pivotal TENT-A3 trial published in Nature Communications in August 2024 was a controlled multi-site study demonstrating that Lenire’s bimodal neuromodulation was clinically superior to sound-only stimulation. Among participants who saw no clinically meaningful improvement from six weeks of sound-only treatment, 70.5% achieved clinically significant improvement once the tongue stimulation component was added.

First U.S. real-world data. In April 2025, the first peer-reviewed real-world U.S. outcomes data for Lenire was published in Nature Communications Medicine by audiologist Dr. Emily McMahan, Au.D., and University of Minnesota Professor Hubert Lim, Ph.D. The study analyzed 220 patients treated at the Alaska Hearing & Tinnitus Center between May 2023 and March 2024. Of 212 patients with available outcome data, 91.5% achieved a clinically significant reduction in tinnitus severity. The mean improvement was 27.8 THI points — well above the 7-point minimally clinically important difference. No device-related serious adverse events were reported. A second real-world study published in the American Journal of Audiology in January 2026 replicated findings at an independent site and further supported Lenire’s generalizability across clinical settings.

Medical infographic explaining how Lenire bimodal neuromodulation works for tinnitus — showing auditory pathway from headphones and trigeminal nerve pathway from tongue stimulation converging at the brain for targeted neuroplasticity. Includes treatment protocol, candidacy criteria, and 91.5% real-world responder rate. Timpanogos Hearing & Tinnitus, one of 14 preferred Lenire provider clinics in the United States.

💡 Clinician’s Note

Timpanogos Hearing & Tinnitus is one of only 14 preferred provider clinics for Lenire in the United States. We’ve integrated it as a core tool for patients with moderate-to-severe tinnitus who have not reached their treatment goals with hearing aids and CBT alone. What I’ve observed clinically aligns with the published data — patients who have plateaued on other approaches frequently see meaningful improvement. Patient selection matters: Lenire is not appropriate for everyone, and candidacy is determined through comprehensive evaluation. — Dr. Layne Garrett, Au.D.

The Susan Shore / Auricle Device — Not Yet FDA-Approved

A second bimodal neuromodulation device — developed by Professor Susan Shore, Ph.D., at the University of Michigan and now being pursued for FDA clearance by the company Auricle, Inc. — has generated significant attention in the tinnitus community and deserves an honest clinical assessment.

The Shore device uses a different mechanism from Lenire. It delivers auditory stimulation through an earbud combined with mild electrical stimulation to the jaw or neck, based on the principle of spike-timing-dependent plasticity — precisely timed stimulation designed to reduce the firing rate of neurons in the cochlear nucleus believed to generate the tinnitus signal. A double-blind crossover randomized clinical trial published in JAMA Otolaryngology–Head & Neck Surgery in 2023 enrolled 99 participants with somatic tinnitus and found statistically significant reductions in tinnitus loudness and Tinnitus Functional Index scores, with effects persisting into the washout period — suggesting durable neuroplastic changes.

Two important clinical limitations apply. First, the Shore device targets somatic tinnitus specifically — a subtype in which jaw, neck, or facial movements modulate the loudness or pitch of the tinnitus. Patients whose tinnitus is not somatically modifiable are unlikely to be candidates, which significantly narrows applicability compared to Lenire. Second, as of early 2026, Auricle has not received FDA clearance and has not confirmed a public submission timeline. Based on standard De Novo review timelines, clearance is unlikely before late 2026 at the earliest — and that estimate assumes submission has already occurred.

Advising patients to defer available, FDA-approved treatment while waiting for a device without a confirmed release date is not clinically supportable. The article on why Dr. Garrett recommends patients not wait for the Susan Shore deviceaddresses this question directly.

⬛ Bottom Line: Two bimodal neuromodulation devices are in the clinical picture. Lenire is FDA-approved, available now through specialized clinics, and indicated for the broad population of patients with moderate-to-severe tinnitus regardless of somatic modulation. The Shore/Auricle device shows genuine scientific promise — particularly for somatic tinnitus — but is not yet available and has no confirmed FDA clearance timeline. These are not equivalent options.

Cognitive Behavioral Therapy: The Most Evidence-Backed Approach

Cognitive behavioral therapy is the single most evidence-supported treatment for the distress caused by tinnitus — by the ringing, buzzing, and ear noise that creates anxiety, disrupts sleep, and interferes with concentration. According to the AAO-HNS Clinical Practice Guideline for Tinnitus, CBT carries the guideline’s strongest recommendation — a Level A rating — meaning it is based on high-quality evidence and recommended for most patients with persistent, bothersome tinnitus. This is the highest evidence tier in the guideline, placing CBT ahead of every other intervention in the evidence hierarchy.

CBT for tinnitus does not attempt to eliminate the sound. Instead, it targets the cognitive and emotional responses that transform a sound perception into a chronic source of suffering. It identifies and restructures negative automatic thoughts — beliefs such as “this will ruin my life” or “I’ll never sleep again” — and replaces them with more realistic, adaptive patterns of thinking. It also incorporates behavioral strategies including relaxation training, graded exposure, sleep hygiene, and auditory desensitization.

A meta-analysis of 15 randomized controlled trials (1,091 participants) published in Clinical Psychology Review found CBT produced statistically significant effects on tinnitus-specific distress compared to both passive and active controls, with effect sizes of Hedges’s g = 0.70 and g = 0.44, respectively — effects maintained at follow-up. A Cochrane review of 28 studies (2,733 participants) confirmed that CBT leads to significant improvements in tinnitus-related quality of life and reductions in depression compared to audiological care, tinnitus retraining therapy, and other active treatments.

In-Person CBT

Tinnitus-trained psychologists, audiologists, and other mental health clinicians can deliver CBT in individual or group formats. Individual sessions allow highly personalized treatment and are appropriate for patients with significant anxiety, depression, or complex presentations. Group formats offer the additional benefit of normalizing the experience — hearing others describe the same struggles and progress is often profoundly relieving for patients who have felt isolated by their condition.

Digital and App-Based CBT

Access to in-person CBT specialists is limited across much of the Wasatch Front outside Salt Lake City. Internet-delivered CBT addresses that barrier directly and has been shown in multiple studies to produce outcomes comparable to in-person delivery.

Timpanogos Hearing & Tinnitus created My Tinnitus Therapy — a structured, audiology-informed digital CBT program developed specifically for tinnitus patients. It is a self-paced program that patients can work through on their own schedule with professional support integrated throughout, and it is available exclusively through Timpanogos Hearing & Tinnitus. For patients who prefer additional independent digital options, two evidence-backed programs are worth knowing about:

  • Oto — a UK-developed guided tinnitus CBT program with clinical backing, accessible in the U.S. through its app platform.
  • Kalmeda — a CE-marked medical device in Europe; a nine-month smartphone-based CBT randomized controlled trial published in the Journal of Medical Internet Research (2025) found statistically significant reductions in tinnitus burden compared to a waiting-list control, with a large effect size.

A 2022 randomized controlled trial of audiologist-delivered internet-based CBT published in the Journal of Medical Internet Research (Beukes et al.) found significantly greater reductions in tinnitus distress compared to weekly monitoring, with benefit maintained at two-month follow-up.

One important limitation: unguided, fully self-directed CBT apps have higher dropout rates than guided or partially guided formats. Digital programs work best when integrated into a supervised clinical plan with a provider supporting engagement.

⬛ Bottom Line: CBT is not a consolation prize when other treatments haven’t worked. It is the treatment with the most robust evidence base in the tinnitus field, and it should be part of any treatment plan from the beginning — not a last resort.

Lifestyle Modifications With Demonstrated Research Support

Lifestyle factors are not usually the primary driver of tinnitus, but a growing body of research suggests they meaningfully influence severity and the nervous system’s reactivity to the tinnitus signal. These are not cures, and no single change will resolve the condition. But they are evidence-informed levers fully under the patient’s control — and they matter more for patients with tinnitus than the same modifications do for the general population.

Physical Activity and Movement

Multiple studies have found associations between physical inactivity, obesity, and increased tinnitus severity. A 2022 randomized trial in Auris Nasus Larynx found that combined diet and exercise specifically reduced tinnitus severity in overweight individuals. Exercise has well-established effects on stress hormones, autonomic nervous system balance, and sleep architecture — all of which intersect directly with tinnitus reactivity. Consistency matters more than type; moderate aerobic activity — walking, cycling, swimming — is beneficial without the acoustic trauma risk of high-intensity gym environments.

Sleep

Sleep disruption and tinnitus are bidirectional: tinnitus interferes with sleep, and poor sleep makes tinnitus more intrusive. Evidence-based strategies overlap substantially with CBT for insomnia techniques: consistent sleep and wake times, limiting time in bed while awake, sound enrichment at night, and reducing caffeine after midday. A practical review is available in the article on sleep tips for tinnitus that actually work.

Diet

A 2022 large-scale survey published in Nutrients (Marcrum et al.) found meaningful associations between dietary patterns and self-reported tinnitus severity. Anti-inflammatory patterns — higher in vegetables, whole grains, and omega-3s; lower in processed foods, refined sugar, and sodium — appear associated with lower tinnitus burden. The question of whether what you eat actually affects the ringing in your ears examines the specific dietary evidence in more depth.

Stress Management

Stress is the second most commonly self-reported tinnitus trigger, after noise trauma, according to Apple Hearing Study data from over 72,000 Apple Watch users analyzed by the University of Michigan School of Public Health. The relationship between stress and tinnitus is clinically well-established: stress activates the sympathetic nervous system and increases the likelihood that the tinnitus signal will be interpreted as dangerous. Structured stress management practices — mindfulness, diaphragmatic breathing, progressive muscle relaxation, regular physical activity — have consistent support as complementary strategies that reinforce CBT work between sessions.

Monitoring Treatment: Heart Rate Variability

Heart rate variability (HRV) measures the variation in time between successive heartbeats and functions as a non-invasive window into the balance between the autonomic nervous system’s sympathetic and parasympathetic branches. Lower HRV is associated with chronic sympathetic activation, higher perceived stress, and reduced resilience.

The connection between HRV and tinnitus has biological grounding. A published study comparing tinnitus patients to healthy controls found that tinnitus patients had significantly lower high-frequency HRV power and higher low-to-high frequency ratios — both markers of sympathetic dominance. A 2021 study in the Journal of Speech, Language, and Hearing Research found that successful acoustic therapy not only reduced tinnitus handicap scores but produced a statistically significant increase in HRV, suggesting that objective autonomic improvement accompanies subjective symptom relief. The University of Michigan Apple Hearing Study analysis — drawn from 72,229 individuals who wore Apple Watches and completed tinnitus surveys — found that lower HRV was associated with higher tinnitus severity, with stress as a key mediating variable.

Circular diagram showing the stress-tinnitus feedback cycle — tinnitus perception triggers stress response, which activates heightened vigilance, which increases distress, which amplifies tinnitus perception. Center shows how HRV monitoring tracks autonomic state to detect where treatment is working. Timpanogos Hearing & Tinnitus, American Fork, Spanish Fork and South Jordan Utah.

As a founding member of the Modern Tinnitus Specialty Center network, Timpanogos Hearing & Tinnitus is among the first tinnitus clinics in the country to integrate HRV monitoring directly into treatment protocols. HRV tracking establishes a physiological baseline that validated instruments like the Tinnitus Handicap Inventory cannot provide, detects treatment response even on subjectively difficult days, and helps identify personal triggers by mapping HRV patterns against sleep quality, stress events, and lifestyle variables. HRV monitoring does not replace validated tinnitus outcome measures — it adds an objective layer most practices do not offer.

One additional dimension worth understanding: effectively treated tinnitus does more than reduce the perceived sound. Research on hearing loss and cognitive health makes clear that chronic auditory stress — the constant attentional demand of monitoring unwanted noise — represents a significant cognitive load. Reducing tinnitus distress through evidence-based treatment frees up the cognitive resources that bothersome tinnitus chronically consumes. For patients concerned about the long-term relationship between hearing, tinnitus, and brain health, the complete guide to hearing loss and cognitive health on this site covers that research in depth.

What Doesn’t Work — and What the Guidelines Say to Avoid

The AAO-HNS guideline is specific about what clinicians should not routinely recommend. This matters because the tinnitus supplement and alternative treatment market is large, persuasive, and largely unsupported by evidence.

Medications

The guideline states that clinicians should NOT routinely recommend antidepressants, anticonvulsants, or anxiolytics for the primary indication of treating tinnitus. Available medications have not demonstrated efficacy specifically for tinnitus symptoms. Treating a co-existing anxiety disorder or depression is appropriate, but prescribing medication specifically to reduce tinnitus is not supported by evidence-based guidelines. The article on whether tinnitus medications actually work covers this in clinical detail.

Supplements

The AAO-HNS guideline explicitly recommends against ginkgo biloba, melatonin, zinc, and other dietary supplements for treating persistent, bothersome tinnitus. This is a positive recommendation against use — not simply an absence of support. Multiple trials of ginkgo biloba specifically for tinnitus have failed to demonstrate benefit over placebo. The evidence on ginkgo biloba for tinnitus and CBD for tinnitus are examined in dedicated articles.

Transcranial Magnetic Stimulation

The guideline advises against the routine use of TMS for tinnitus. Evidence has been inconsistent and no FDA clearance exists for TMS as a tinnitus-specific treatment. TMS should not be confused with bimodal neuromodulation like Lenire, which is a distinct mechanism with FDA De Novo approval.

Acupuncture

The guideline states that no recommendation can be made regarding acupuncture for tinnitus — meaning evidence is insufficient to support or refute it. Insufficient evidence is not evidence of effectiveness.

Binaural Beats and Unvalidated Digital Products

A wide range of audio products, apps, and YouTube programs claim to treat or cure tinnitus through binaural beats or proprietary sound patterns. None have peer-reviewed clinical trial evidence supporting their use. A clinical assessment is available in the article on binaural beats for tinnitus, and a review of red light therapy claims is at the article on whether red light therapy for tinnitus is a breakthrough or bust.

The table below summarizes the treatment landscape based on current guideline recommendations. “Recommended” means supported by clinical evidence and named in the AAO-HNS or VA/DOD guidelines. “Not recommended” means the guideline explicitly advises against use, or evidence is insufficient to support it.

Tinnitus treatment comparison table showing evidence status and AAO-HNS guideline position for 12 treatments including hearing aids, CBT, Lenire, ginkgo biloba, and TMS — color coded teal for supported, red for not recommended, amber for insufficient evidence. Source: Timpanogos Hearing & Tinnitus.

⬛ Bottom Line: If a product claims to cure tinnitus, reduce it “permanently,” or uses testimonials in place of clinical trial data, those are reliable signals to apply skepticism. The treatments with the most evidence — CBT, hearing aids, sound therapy, and bimodal neuromodulation — do not promise elimination. They promise meaningful, evidence-based reduction in how much tinnitus affects daily life.

Investigational Drugs in Clinical Trials

No FDA-approved medication exists for tinnitus as of 2026. Multiple pharmaceutical approaches are in active or recently completed trials, and some show genuine promise.

OTO-313 (Gacyclidine)

OTO-313, developed by Otonomy, Inc., is an intratympanic injection of gacyclidine — an NMDA receptor antagonist delivered through the eardrum to the inner ear. The mechanism targets glutamate excitotoxicity believed to contribute to tinnitus onset following noise or acoustic trauma. A Phase 2 randomized, placebo-controlled trial published in European Archives of Oto-Rhino-Laryngology (2023) enrolled patients with unilateral tinnitus of 2–12 months’ duration. Both groups showed similar improvement, with no statistically significant difference between OTO-313 and placebo — a result that illustrates the substantial placebo response in tinnitus trials and the challenge this creates for drug development.

SPI-1005 (Ebselen)

SPI-1005, developed by Sound Pharmaceuticals, contains ebselen — a compound mimicking glutathione peroxidase, an enzyme important to inner ear cell protection. It was studied primarily in Menière’s disease, where both hearing loss and tinnitus are central symptoms. The STOPMD-3 Phase 3 trial completed enrollment and follow-up by July 2024, making it one of the longest investigational drug trials ever completed for a hearing loss or tinnitus indication. Results were being analyzed and presented through early 2025.

The Challenge of Drug Development for Tinnitus

The high placebo response rate in tinnitus trials — often 30–40% improvement in placebo groups — makes it exceptionally difficult to isolate drug-specific effects. Researchers are actively developing better trial designs, patient stratification biomarkers, and objective outcome measures to address this. Patients interested in participating in tinnitus drug trials can search active studies at ClinicalTrials.gov.

How a Complete Treatment Plan Comes Together

The patients who make the most progress are those in a structured, multimodal plan — not those pursuing any single intervention in isolation. Hearing aids with verified Real Ear Measurement address the auditory environment and the amplification gap most tinnitus patients are living with. CBT addresses cognitive and emotional reactivity. Lenire, for qualifying patients, addresses the underlying neural activity. Lifestyle modifications reduce the physiological load. HRV monitoring provides objective visibility into how the nervous system is responding.

ertical flowchart showing a complete six-step tinnitus treatment plan at Timpanogos Hearing & Tinnitus — from comprehensive diagnostic evaluation through hearing aids with Real Ear Measurement, cognitive behavioral therapy, Lenire bimodal neuromodulation for qualifying patients, lifestyle modifications, and HRV monitoring. Source: utahhearingaids.com.

For most patients in American Fork, Spanish Fork, Salt Lake City, Provo, or elsewhere on the Wasatch Front presenting with persistent, bothersome tinnitus, a reasonable starting framework looks like this:

A comprehensive diagnostic evaluation — including audiometric testing, tinnitus characterization, and medical history review — to identify the type of tinnitus and relevant contributing factors. The article on how the type of tinnitus determines whether treatment works explains the clinical distinctions.

If hearing loss is present — which it is for most tinnitus patients, even those who feel they hear fine — hearing aid evaluation with Real Ear Measurement verification. This is the most frequently overlooked intervention in tinnitus management and the one with the lowest barrier to entry.

CBT, initiated early as a first-line intervention rather than a last resort — either in-person, through My Tinnitus Therapy, or another supervised digital program.

For patients with moderate or worse tinnitus severity (THI ≥ 38) who are appropriate candidates, evaluation for Lenire bimodal neuromodulation — particularly for those who have not reached their treatment goals with hearing aids and CBT alone.

Lifestyle modifications integrated throughout as a parallel track that extends the benefit of clinical treatment into daily life.

HRV monitoring as an objective biomarker layer for patients who want data-informed feedback on their treatment trajectory.

None of this happens without a clinician who understands tinnitus, not just hearing loss. The scope of what’s described here — bimodal neuromodulation, HRV integration, structured CBT delivery, Real Ear Measurement — is not standard care at most general audiology or ENT practices. The article on finding a real tinnitus specialist after a hearing aid disappointment provides a practical framework for evaluating any prospective provider.

Patients interested in exploring whether they’re a candidate for treatment at Timpanogos Hearing & Tinnitus are welcome to schedule a consultation at our American Fork, Spanish Fork, or South Jordan (opening Spring 2026) locations.

Frequently Asked Questions

Will tinnitus treatment make the ringing in my ears go away?

For most patients, the goal is not silence — it is habituation and reduced distress. Habituation means the nervous system stops treating the tinnitus signal as a threat, so the ringing, buzzing, or ear noise recedes into the background of awareness the way a refrigerator hum does. Many patients reach a point where they are rarely aware of their tinnitus during daily life. A smaller number experience a significant reduction in the loudness or prominence of the sound itself. Complete, permanent elimination is possible but cannot be reliably predicted for any individual patient. What can be predicted, based on substantial research, is that structured, evidence-based treatment produces meaningful improvement in quality of life for the majority of patients who engage with it consistently.

Am I a candidate for Lenire?

Lenire is FDA-approved for adults 18 and older with at least moderate tinnitus severity, defined as a Tinnitus Handicap Inventory score of 38 or above. Candidacy also involves a comprehensive audiologic evaluation and medical history review. Patients with certain contraindications — including those who cannot tolerate intraoral devices — may not be candidates. The determination is made through clinical evaluation, not a checklist, which is one reason Lenire is available only through specialized preferred provider clinics. Somatic tinnitus is not required.

How long does tinnitus treatment take?

It depends substantially on the treatment approach and the individual patient. Lenire involves two 30-minute daily sessions over approximately 12 weeks. CBT programs — in-person or digital — typically run 8 to 16 weeks for the core intervention, with continued benefit documented beyond that period. Hearing aid acclimatization generally unfolds over several months. Tinnitus management is not a two-week program. Patients who approach it as a structured, multi-month commitment to a complete plan see the best outcomes.

I tried a hearing aid before and it didn’t help my tinnitus. Does that mean hearing aids won’t work for me?

Not necessarily. The most common reason a hearing aid fails to help with tinnitus is that the fitting was never verified with Real Ear Measurement — meaning the device may not have been delivering the right amplification at the frequencies where it matters most for tinnitus relief. Before concluding that hearing aids cannot help, it is worth confirming whether your previous fitting included that verification. A properly verified fitting is a different clinical intervention than an unverified one.

Can I monitor HRV myself with a smartwatch?

Yes, and for many patients it provides genuinely useful data. Apple Watch, Garmin, Oura Ring, and similar wearables all measure HRV and track trends over time. The challenge is interpretation — understanding what your HRV data means in the context of tinnitus treatment requires clinical guidance. Raw HRV numbers vary by individual, time of day, age, and measurement method, so tracking your own trend over time is more useful than comparing to population averages. At Timpanogos Hearing & Tinnitus, HRV data from wearables is incorporated into the treatment monitoring process as an objective complement to validated tinnitus outcome measures.

Are there any supplements that help tinnitus?

The AAO-HNS guideline explicitly recommends against ginkgo biloba, zinc, and melatonin for treating tinnitus, based on the available evidence. No dietary supplement has demonstrated reliable efficacy for tinnitus in peer-reviewed clinical trials. The supplement market for tinnitus is large and heavily marketed, but the clinical evidence does not support it.

My doctor told me to just learn to live with the ringing in my ears. Is that still the standard of care?

It is not, and it has not been for over a decade. The AAO-HNS clinical practice guideline was published in 2014 and specifically recommends that clinicians educate patients with persistent, bothersome tinnitus about management strategies rather than offering reassurance alone or dismissing the complaint. A physician or audiologist who responds to bothersome tinnitus with “nothing can be done” is not reflecting current evidence-based standards of care.

What is the difference between a general audiologist and a tinnitus specialist?

The credential distinction matters less than the clinical process. What separates meaningful tinnitus care from a routine hearing aid fitting is diagnostic depth, the range of available interventions, and the structure of the treatment plan. A genuine tinnitus specialist will perform comprehensive tinnitus characterization beyond a standard audiogram, offer CBT as a first-line option rather than an afterthought, have access to sound therapy and neuromodulation options, and track progress with validated outcome measures. A useful set of questions to ask any prospective tinnitus provider is covered in the article on finding a real tinnitus specialist.

When the Ringing in Your Ears Warrants a Specialist Evaluation

Not every episode of ear ringing requires a specialist. Tinnitus that lasts a few hours after a loud concert and then resolves is common and typically not a clinical concern. But there are specific circumstances where prompt evaluation matters — both to rule out underlying conditions and to start effective treatment before the neural patterns driving tinnitus become more entrenched.

See an audiologist or ENT promptly if:

  • Tinnitus has persisted for more than two to four weeks without a clear, resolving cause
  • The ringing is only in one ear — unilateral tinnitus warrants evaluation to rule out vascular lesions or vestibular schwannoma
  • Tinnitus is accompanied by sudden or progressive hearing loss
  • The sound pulses in rhythm with your heartbeat — this is pulsatile tinnitus and requires vascular evaluation
  • Tinnitus is accompanied by dizziness, vertigo, or balance problems
  • The ringing is severe enough to interfere with sleep, concentration, work, or relationships

See a tinnitus specialist specifically — not just a general audiologist — if:

  • You’ve already been evaluated and told nothing can be done
  • You’ve tried hearing aids that didn’t help your tinnitus and never received an explanation why
  • Tinnitus is significantly affecting your quality of life and you haven’t been offered CBT, sound therapy, or neuromodulation as options
  • You’re researching Lenire or other bimodal neuromodulation and want to establish candidacy
  • You have moderate-to-severe tinnitus with THI score of 38 or above — this is the threshold where the full range of evidence-based interventions applies
Not sure where your tinnitus falls on the severity spectrum? The tool below takes about two minutes and gives you a score with a specific recommendation.

The distinction between a general audiology visit and a specialty tinnitus evaluation is meaningful. A general audiologist can rule out underlying causes, fit hearing aids, and recommend sound therapy. A tinnitus specialty practice goes further: comprehensive tinnitus characterization, structured CBT delivery, neuromodulation candidacy assessment, validated outcome tracking, and lifestyle protocol. If you’re in the Wasatch Front area and have been through a general evaluation without adequate relief, the next step is a specialist.

Tinnitus Treatment on the Wasatch Front — What Patients in Utah Should Know

Tinnitus care in Utah County and the greater Salt Lake Valley ranges widely in depth and available interventions. Most primary care providers and general ENT practices offer limited tinnitus-specific guidance — typically a referral for a hearing test and, if hearing loss is present, a recommendation for hearing aids. Some audiology clinics go further with sound therapy. Very few offer structured CBT, validated outcome tracking, or access to bimodal neuromodulation.

For patients across the Wasatch Front — in communities like American Fork, Lehi, Provo, Orem, Pleasant Grove, Spanish Fork, Salt Lake City, Murray, Sandy, Draper, and South Jordan — the relevant question before choosing where to seek tinnitus care is not which provider is closest. It is which provider offers the full range of evidence-based interventions and has the clinical infrastructure to deliver them. Specifically:

  • Does the provider use Real Ear Measurement on every hearing aid fitting, or are devices programmed by software estimate alone?
  • Is CBT offered as a first-line intervention, or only mentioned if everything else fails?
  • Does the provider have access to Lenire or other neuromodulation options for patients with moderate-to-severe tinnitus?
  • Are treatment outcomes tracked using validated instruments like the Tinnitus Handicap Inventory or Tinnitus Functional Index?

Timpanogos Hearing & Tinnitus — with locations in American Fork, Spanish Fork, and South Jordan (opening Spring 2026) — is Utah’s only full-time tinnitus specialty center and the first clinic in Utah trained and licensed to provide Lenire therapy. It is also the only practice in Utah offering all three primary evidence-based tinnitus treatment modalities — hearing devices with Real Ear Measurement verification, Lenire bimodal neuromodulation, and My Tinnitus Therapy, the practice’s proprietary CBT program — under one roof. Patients travel from across Utah, Salt Lake, Davis, and Wasatch counties for tinnitus evaluation when local options have been exhausted.

What to Expect at a Tinnitus Specialty Evaluation

Many patients have been to a general hearing clinic before presenting at a tinnitus specialty practice. The experience is different in ways worth knowing in advance.

A comprehensive tinnitus evaluation at a specialty center is not a hearing screening. It typically runs 60 to 90 minutes and covers considerably more ground than a standard audiogram. Expect assessment of your full audiometric profile across extended frequencies, characterization of your tinnitus pitch and loudness, evaluation of minimum masking levels, review of tinnitus-related distress using validated instruments, discussion of your tinnitus history and any prior treatment attempts, and a systematic review of contributing factors including sleep, stress, cardiovascular health, and medications.

The outcome of that evaluation is a specific treatment recommendation — not a general suggestion to “try a hearing aid” or “learn to manage it.” A well-run specialty evaluation results in a mapped treatment plan with defined interventions, a timeline, and objective benchmarks for tracking progress.

At Timpanogos Hearing & Tinnitus, every new tinnitus patient receives that level of evaluation before any recommendation is made. The goal is not to sell a device. It is to determine which specific combination of interventions — verified hearing aids, structured CBT, My Tinnitus Therapy, Lenire, lifestyle modification, HRV monitoring — gives that patient the best realistic chance of meaningful improvement.

If you’ve been told nothing can be done — or if you’ve tried one approach and hit a wall — a comprehensive tinnitus evaluation is the right next step. Not a hearing screening. Not a device demonstration. A clinical evaluation that maps your specific tinnitus profile to the interventions most likely to help.

Timpanogos Hearing & Tinnitus is Utah’s only full-time tinnitus specialty center, a founding member of the Modern Tinnitus Specialty Center network, and one of only 14 preferred Lenire provider clinics in the United States.

Timpanogos Hearing & Tinnitus

American Fork, UT — (801) 763-0725 | Spanish Fork, UT — (801) 798-7210 | South Jordan, UT — Opening Spring 2026

Request Your Consultation

References & Further Reading

  1. Tunkel DE, Bauer CA, Sun GH, et al. Clinical Practice Guideline: Tinnitus. Otolaryngology–Head and Neck Surgery. 2014;151(2_suppl):S1–S40. https://doi.org/10.1177/0194599814545325
  2. Roberts L, Salvi R, Bhatt J, et al. Clinical Practice Guideline for Management of Tinnitus: Recommendations From the US VA/DOD Clinical Practice Guideline Work Group. JAMA Otolaryngology–Head & Neck Surgery. Published online March 20, 2025. https://doi.org/10.1001/jamaoto.2025.0052
  3. McMahan EE, Lim HH. Retrospective chart review demonstrating effectiveness of bimodal neuromodulation for tinnitus treatment in a clinical setting. Communications Medicine. 2025;5:112. https://doi.org/10.1038/s43856-025-00837-3
  4. Boedts M, Buechner A, Khoo SG, et al. Combining sound with tongue stimulation for the treatment of tinnitus: a multi-site single-arm controlled pivotal trial. Nature Communications. 2024;15:6806. https://doi.org/10.1038/s41467-024-50473-z
  5. Bimodal neuromodulation for tinnitus in a clinical practice setting. American Journal of Audiology. 2026. https://pubs.asha.org/doi/10.1044/2025_AJA-25-00090
  6. Martel DT, Schvartz-Leyzac KC, Shore SE. Reversing Synchronized Brain Circuits Using Targeted Auditory-Somatosensory Stimulation to Treat Phantom Percepts: A Randomized Clinical Trial. JAMA Otolaryngology–Head & Neck Surgery. 2023. https://pubmed.ncbi.nlm.nih.gov/37266943/
  7. Hesser H, Weise C, Westin VZ, Andersson G. A systematic review and meta-analysis of randomized controlled trials of cognitive-behavioral therapy for tinnitus distress. Clinical Psychology Review. 2011;31(4):545–553. https://doi.org/10.1016/j.cpr.2010.12.006
  8. Fuller T, Cima R, Langguth B, et al. Cognitive behavioural therapy for tinnitus. Cochrane Database of Systematic Reviews. 2020;(1):CD012614. https://doi.org/10.1002/14651858.CD012614.pub2
  9. Beukes EW, Andersson G, Fagelson MA, Manchaiah V. Internet-Based Audiologist-Guided Cognitive Behavioral Therapy for Tinnitus: Randomized Controlled Trial. Journal of Medical Internet Research. 2022;24(2):e27584. https://doi.org/10.2196/27584
  10. Walter U, Pennig S, Bleckmann L, et al. Continuous Improvement of Chronic Tinnitus Through a 9-Month Smartphone-Based Cognitive Behavioral Therapy: Randomized Controlled Trial. Journal of Medical Internet Research. 2025;27:e59575. https://doi.org/10.2196/59575
  11. Searchfield GD, Durai M, Linford T. Changes in Heart Rate Variability Following Acoustic Therapy in Individuals With Tinnitus. Journal of Speech, Language, and Hearing Research. 2022;65(3):844–857. https://doi.org/10.1044/2021_JSLHR-20-00596
  12. University of Michigan School of Public Health / Apple Hearing Study. Apple Hearing Study Identifies Connection Between Tinnitus and Heart Rate Variability in Adults. 2025. https://sph.umich.edu/applehearingstudy/study-updates/tinnitus%20and%20hrv.html
  13. Özbey-Yücel Ü, Aydoğan Z, Tokgoz-Yilmaz S, et al. The effects of diet and physical activity induced weight loss on the severity of tinnitus and quality of life. Auris Nasus Larynx. 2023;50(1):40–47. https://doi.org/10.1016/j.anl.2022.04.013
  14. Marcrum SC, Engelke M, Goedhart H, et al. The influence of diet on tinnitus severity: results of a large-scale, online survey. Nutrients. 2022;14:5356. https://doi.org/10.3390/nu14245356
  15. Wadhwa S, Jain S, Patil N. The Role of Diet and Lifestyle in the Tinnitus Management: A Comprehensive Review. Cureus. 2024;16(4):e59344. https://doi.org/10.7759/cureus.59344
  16. OTO-313 Phase 2 randomized controlled study. European Archives of Oto-Rhino-Laryngology. 2023. https://link.springer.com/article/10.1007/s00405-023-08047-0
  17. Baguley D, McFerran D, Hall D. Tinnitus. Lancet. 2013;382(9904):1600–1607. https://pubmed.ncbi.nlm.nih.gov/24120114/

About the Author

Dr. Layne Garrett, Au.D., FAAA, ABAC, CH-TM, CDP is the founder of Timpanogos Hearing & Tinnitus, with locations in American Fork and Spanish Fork, Utah. He holds a doctorate in audiology and board certification through the American Board of Audiology, with specialty certifications in tinnitus management (CH-TM) and dementia care (CDP). Dr. Garrett has spent more than 20 years specializing in hearing loss and tinnitus—with a particular clinical focus on patients who have been told their tinnitus is untreatable, or whose prior hearing aid experiences were unsuccessful. His 90% tinnitus success rate reflects both the depth of his evaluation protocols and a comprehensive, multimodal treatment approach that most general audiology practices do not offer. Timpanogos Hearing & Tinnitus is one of only 14 preferred provider clinics for Lenire bimodal neuromodulation therapy in the United States, among the first clinics in the country to integrate Heart Rate Variability monitoring into tinnitus treatment, and an early adopter of LACE-AI Pro auditory rehabilitation protocols. Every hearing aid fitting at Timpanogos Hearing & Tinnitus includes Real Ear Measurement verification—a standard performed by fewer than 30% of clinics nationwide. Dr. Garrett participates in humanitarian audiology missions through Hearing the Call and operates a local program providing hearing aids at no cost to qualifying Utah residents earning below 250% of the federal poverty level. Timpanogos Hearing & Tinnitus has also established a partnership with Bingham Family Clinic to expand access to evidence-based hearing care for underserved patients across the Wasatch Front. He produces regular educational content on audiology, tinnitus, cognitive hearing health, and emerging treatments to help patients and families make fully informed decisions.

Date Reviewed/Modified: March 29, 2026

Similar Posts